Key result
An ELISA using Trypanosoma cruzi epimastigote ribonucleoproteins detected IgG antibodies in 97% of patients with Chagas' disease, with a 1% false-positive rate among controls.
Why the study?
Does an ELISA using Trypanosoma cruzi epimastigote ribonucleoprotein improve diagnostic specificity for Chagas' disease?
Case-Control (n=216)
Yes
Does an ELISA using Trypanosoma cruzi epimastigote ribonucleoprotein improve diagnostic specificity for Chagas' disease?
Absolute Event Rate: 97% vs 1%
An ELISA using Trypanosoma cruzi epimastigote ribonucleoprotein provides high sensitivity (97%) and specificity (99%) for diagnosing Chagas' disease, effectively avoiding cross-reactivity with leishmaniasis.
No takes yet. Share an insight, caveat, or question.
May support Chagas serodiagnosis with high specificity; leaves open prospective validation in endemic settings.
Solana et al. (1995) conducted a case-control in Chagas' disease (n=216). ELISA with Trypanosoma cruzi epimastigote ribosomal fraction vs. Controls without Chagas' disease was evaluated on Presence of IgG antibodies against the ribosomal fraction. An ELISA using Trypanosoma cruzi epimastigote ribonucleoproteins detected IgG antibodies in 97% of patients with Chagas' disease, with a 1% false-positive rate among controls.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: